MMP/TIMP expression profiles in distinct lung disease models: Implications for possible future therapies

Respiratory Research

Volumn 10, Issue 1, 2009, Pages

  Wong, Sissie ^a   Belvisi, Maria G ^a   Birrell, Mark A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGENASE 3; ELASTASE; GELATINASE A; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE; MESSENGER RNA; PANCREATIC ELASTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; EMPHYSEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG LAVAGE; MALE; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFLAMMATION; ANIMAL; BIOSYNTHESIS; BROWN NORWAY RAT; CYTOLOGY; GENETICS; LUNG; LUNG DISEASE; METABOLISM; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; LIPOPOLYSACCHARIDES; LUNG; LUNG DISEASES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; PANCREATIC ELASTASE; PHENOTYPE; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 70249085241     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-72     Document Type: Article

References (19)

1. Babusyte A, Stravinskaite K, Jeroch J, Lotvall J, Sakalauskas R, Sitkauskiene B: Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res 2007, 8:81.
2. Demedts IK, Morel-Montero A, Lebecque S, Pacheco Y, Cataldo D, Joos GF, Pauwels RA, Brusselle GG: Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006, 61:196-201.
3. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT: Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998, 78:1077-1087.
4. Saitoh W, Sakamoto T, Hegab AE, Nomura A, Ishii Y, Morishima Y, Kai S, Iizuka T, Kiwamoto T, Matsuno Y, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K: MMP14 gene polymorphisms in chronic obstructive pulmonary disease. Int J Mol Med 2006, 17:621-626.
5. Araujo BB, Dolhnikoff M, Silva LF, Elliot J, Lindeman JH, Ferreira DS, Mulder A, Gomes HA, Fernezlian SM, James A, Mauad T: Extracellular matrix components and regulators in the airway smooth muscle in asthma. Eur Respir J 2008, 32:61-69.
6. Chiba Y, Yu Y, Sakai H, Misawa M: Increase in the expression of matrix metalloproteinase-12 in the airways of rats with allergic bronchial asthma. Biol Pharm Bull 2007, 30:318-323.
7. Maisi P, Prikk K, Sepper R, Pirila E, Salo T, Hietanen J, Sorsa T: Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS 2002, 110:771-782.
8. Tang LF, Du LZ, Chen ZM, Zou CC: Levels of matrix metalloproteinase-9 and its inhibitor in bronchoalveolar lavage cells of asthmatic children. Fetal Pediatr Pathol 2006, 25:1-7.
9. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De AJ, Newton R, Haj-Yahia S, Pun KT, Watts CJ, Shaw RJ, Savage TJ, Belvisi MG: Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 2005, 172:962-971.
10. Underwood SL, Haddad e, Birrell MA, McCluskie K, Pecoraro M, Dabrowski D, Webber SE, Foster ML, Belvisi MG: Functional characterization and biomarker identification in the Brown Norway model of allergic airway inflammation. Br J Pharmacol 2002, 137:263-275.
11. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG: Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 2005, 19:840-841.
12. Haddad EB, Birrell M, McCluskie K, Ling A, Webber SE, Foster ML, Belvisi MG: Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol JID | 7502536 2001, 132:1715-1724.
13. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG: Steroid-resistant Inflammation in a Rat Model of Chronic Obstructive Pulmonary Disease Is Associated with a Lack of Nuclear Factor-{kappa}B Pathway Activation. Am J Respir Crit Care Med 2005, 172:74-84.
14. McCluskie K, Birrell MA, Wong S, Belvisi MG: Nitric oxide as a noninvasive biomarker of lipopolysaccharide-induced airway inflammation: possible role in lung neutrophilia. J Pharmacol Exp Ther 2004, 311:625-633.
15. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001, 166:1975-1982.
16. Leco KJ, Waterhouse P, Sanchez OH, Gowing KL, Poole AR, Wakeham A, Mak TW, Khokha R: Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001, 108:817-829.
17. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996, 149:273-282.
18. Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SR: MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med 2008, 102:845-851.
19. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005, 6:151.